Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

OVID

Ovid Therapeutics Inc.

Pharmaceutical Preparations · SIC 2834CIK 1636651Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$7.0M
Net Income FY2025
$(17.0M)
EPS (Basic, as reported)
—
Net Margin FY2025
-240.1%
ROE FY2025
-13.3%
Total Equity
$131.0M
Shares Out
195M
Business description

Ovid Therapeutics Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2015–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 13 → 7 -11.6% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue————132082017
Research & development(10)(50)(34)(42)(63)(47)(25)(29)(37)(26)
General & administrative(13)(15)(19)(19)(31)(37)(32)(31)(26)(24)
Total operating expenses(23)(65)(53)(61)(94)(84)(57)(60)(62)(50)
Operating income(23)(65)(53)(61)(81)124(56)(59)(62)(42)
Interest & investment income———————542
Other income (expense), net0011—0173525
Pre-tax income————(81)124(54)(52)(26)(17)
Income tax expense—0000(1)0000
Net income(22)(65)(52)(60)(81)123(54)(52)(26)(17)
EPS — basic————($1.39)$1.78($0.77)($0.74)——
EPS — diluted————($1.39)$1.76($0.77)($0.74)——
Shares outstanding — basic (M)————58677071——
Shares outstanding — diluted (M)————58687071——

Showing the latest 10 of 11 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.